Sameh Hanna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sameh Hanna has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Charles W. Lynde
University of Toronto, Markham, Canada
4 shared publications - Marni Wiseman
Probity Medical Research Inc., Waterloo, ON, Canada
4 shared publications - Vimal H. Prajapati
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Canada
4 shared publications Daniel Wong
DeRMA Skin Institute, Burlington, ON, Canada
3 shared publicationsDimitrios Kyritsis
Clinique de Dermatologie Protoderma, Pierrefonds Medical Center, Montreal, QC, Canada
3 shared publications- Geeta Yadav
FACET Dermatology, University of Toronto, Toronto, ON, Canada
3 shared publications
Latest Publications
- 9 June 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (10) , 1928-1930
Public Perceptions of Suncream Toxicity: A Content Analysis on Reddit
Among 284 Reddit posts expressing sunscreen safety concerns, ingredient toxicity and endocrine disruption were most frequently cited, particularly regarding avobenzone, oxybenzone, and octocrylene. Public concerns appear disproportionate to current human safety data, emphasizing the importance of evidence-based communication.
- 9 June 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (10) , 1928-1930
Public Perceptions of Suncream Toxicity: A Content Analysis on Reddit
Among 284 Reddit posts expressing sunscreen safety concerns, ingredient toxicity and endocrine disruption were most frequently cited, particularly regarding avobenzone, oxybenzone, and octocrylene. Public concerns appear disproportionate to current human safety data, emphasizing the importance of evidence-based communication.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Treatment Options
Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce Malassezia yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Treatment Options
Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce Malassezia yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology
Seborrheic dermatitis is a common chronic dermatosis predominantly affecting sebum-rich areas. The diagnosis of seborrheic dermatitis can be challenging due to its clinical resemblance to other dermatoses. Seborrheic dermatitis can significantly impact quality of life, particularly in those with pruritus and dyspigmentation involving the facial region. The pathogenesis of seborrheic dermatitis is complex, and while its etiology is not yet fully understood, current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction. This review provides an updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis. This is the first in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology
Seborrheic dermatitis is a common chronic dermatosis predominantly affecting sebum-rich areas. The diagnosis of seborrheic dermatitis can be challenging due to its clinical resemblance to other dermatoses. Seborrheic dermatitis can significantly impact quality of life, particularly in those with pruritus and dyspigmentation involving the facial region. The pathogenesis of seborrheic dermatitis is complex, and while its etiology is not yet fully understood, current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction. This review provides an updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis. This is the first in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- Top Cited PapersOpen Access
- 23 July 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 880-888
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- 23 July 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 880-888
Top Cited PapersOpen AccessEfficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- 3 September 2019
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 23 (4_suppl) , 19S-26S
What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
The topical calcineurin inhibitors (TCIs), tacrolimus (Protopic) and pimecrolimus (Elidel), were approved in the early 2000s and were widely used as a nonsteroid treatment for atopic dermatitis (AD) in adult and pediatric populations. In 2005, the addition of a boxed warning was mandated for TCIs based on a potential risk of malignancy, and there was subsequently a substantial decline in their use. Since then, evidence has mounted to support the safety of this class of medications and suggests that the increased risk of malignancy remains theoretical. This review aims to dispel some of the common myths surrounding the safety of TCIs by evaluating the key evidence regarding their safety and tolerability in adult and pediatric populations. Four major themes are addressed in a practical question-and-answer format: the risk of harm associated with TCIs including common and serious adverse events; warnings and precautions for their use including the risk of systemic absorption, immunosuppression, and malignancy; the comparative safety of TCIs; and suggestions for counselling patients about the risk of harm with TCIs. Based on the available evidence, international professional dermatological organizations and regulatory authorities have concluded that the benefits of TCIs outweigh their potential risks when used in the appropriate patient populations for the recommended duration of time.
- 3 September 2019
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 23 (4_suppl) , 19S-26S
What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
The topical calcineurin inhibitors (TCIs), tacrolimus (Protopic) and pimecrolimus (Elidel), were approved in the early 2000s and were widely used as a nonsteroid treatment for atopic dermatitis (AD) in adult and pediatric populations. In 2005, the addition of a boxed warning was mandated for TCIs based on a potential risk of malignancy, and there was subsequently a substantial decline in their use. Since then, evidence has mounted to support the safety of this class of medications and suggests that the increased risk of malignancy remains theoretical. This review aims to dispel some of the common myths surrounding the safety of TCIs by evaluating the key evidence regarding their safety and tolerability in adult and pediatric populations. Four major themes are addressed in a practical question-and-answer format: the risk of harm associated with TCIs including common and serious adverse events; warnings and precautions for their use including the risk of systemic absorption, immunosuppression, and malignancy; the comparative safety of TCIs; and suggestions for counselling patients about the risk of harm with TCIs. Based on the available evidence, international professional dermatological organizations and regulatory authorities have concluded that the benefits of TCIs outweigh their potential risks when used in the appropriate patient populations for the recommended duration of time.